US EditionEli Lilly's Next-Gen Obesity Drug Shows Biggest Weight Loss yet in Clinical Trial
- On Nov. 21, 2025, Eli Lilly announced TRIUMPH-4, a Phase 3, 68-week trial, showed retatrutide’s highest dose averaged 23.7% weight loss in adults with obesity or overweight and knee osteoarthritis.
- Retatrutide, a `triple G` therapy, works by mimicking GLP-1, GIP and glucagon, and Lilly is positioning it as the next pillar after Zepbound in a market some analysts estimate at about $100 billion.
- On-Treatment analysis showed the highest dose delivered 28.7% average weight loss, reduced WOMAC pain score by up to 62.6%, and more than one in eight patients were pain-free at 68 weeks.
- Discontinuations due to adverse events showed rates of 12.2% and 18.2% for retatrutide 9 mg and 12 mg, with gastrointestinal events common and dropout rates "highly correlated" with baseline BMI, Lilly said.
- With seven readouts slated for 2026, Lilly plans to present detailed TRIUMPH-4 findings at a future medical meeting from the program, which began in 2023 and enrolled more than 5,800 participants.
38 Articles
38 Articles
Eli Lilly Weight Loss Drug Shows Impressive Results in Phase 3 Trial
Are you familiar with the term “triple agonist”? If you aren’t now, it might be one to file away for later use, in much the same way that GLP-1 has entered into the broader lexicon. (Actually, there’s another reason to associate these two terms, but we’ll get to that shortly.) This week, the pharmaceutical company Eli Lilly shared the results of a Phase 3 clinical trial for the drug retatrutide, which is used to treat patients with both obesity …
Lilly's next-gen drug shows greater weight loss than Zepbound in late-stage trial
New Lilly drug outperforming Zepbound (REUTERS) — Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a late-stage trial, outperforming its blockbuster drug Zepbound and reinforcing the company’s lead in the fast-growing market. The global obesity market has surged in recent years on strong demand for GLP-1-based drugs like Zepbound and Novo Nordisk’s Wegovy, prompting drugmaker…
Eli Lilly drug helped trial patients shed 29% of weight
Eli Lilly said its new obesity drug delivered more weight loss than any existing medication. Patients taking the injectable, which aims to rival Novo Nordisk’s Wegovy, lost an average of 71 pounds, or 29% of their body weight in the late-stage trial. (Wegovy averages 15%.) Some lost so much weight they dropped out of the trial, and many reported relief from arthritis symptoms. Pharmaceutical giants are racing to deliver next-generation treatment…
Coverage Details
Bias Distribution
- 64% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
